NASDAQ:TXMD - TherapeuticsMD Stock Price, Forecast & News

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings data on Thursday, February, 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.01. The business earned $15.90 million during the quarter, compared to analyst estimates of $12.82 million. TherapeuticsMD had a negative net margin of 354.79% and a negative return on equity of 1,047.83%. The firm's quarterly revenue was up 212.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS. View TherapeuticsMD's Earnings History.

TherapeuticsMD is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for TherapeuticsMD.

TherapeuticsMD updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90-110 million, compared to the consensus revenue estimate of $100.15 million.

9 brokers have issued 12 month price targets for TherapeuticsMD's stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate TherapeuticsMD's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 336.9% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.

Press coverage about TXMD stock has trended very negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. TherapeuticsMD earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in January. As of January 15th, there was short interest totalling 86,820,000 shares, an increase of 9.4% from the December 31st total of 79,360,000 shares. Based on an average daily volume of 3,670,000 shares, the days-to-cover ratio is currently 23.7 days. Currently, 36.6% of the shares of the company are short sold. View TherapeuticsMD's Current Options Chain.

Some companies that are related to TherapeuticsMD include Karuna Therapeutics (KRTX), Epizyme (EPZM), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX), Synthorx (THOR), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Pacira Biosciences (PCRX), Forty Seven (FTSV), Xencor (XNCR), Eidos Therapeutics (EIDX), Cambrex (CBM), Heron Therapeutics (HRTX) and Ironwood Pharmaceuticals (IRWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include Opko Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Cleveland-Cliffs (CLF), CannTrust (CNTTF), NVIDIA (NVDA), Horizon Therapeutics (HZNP), Inovio Pharmaceuticals (INO), Global Blood Therapeutics (GBT) and Novavax (NVAX).

TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (6.52%), Bank of New York Mellon Corp (4.84%), Franklin Resources Inc. (3.50%), State Street Corp (2.04%), Bamco Inc. NY (1.41%) and Stifel Financial Corp (1.11%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Daniel A Cartwright, Group L P Column, Jane F Barlow, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, FMR LLC, Franklin Resources Inc., Sanders Morris Harris LLC, SG Americas Securities LLC, Raymond James & Associates and First Eagle Investment Management LLC. View Insider Buying and Selling for TherapeuticsMD.

TXMD stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Marshall Wace North America L.P., State Street Corp, Knights of Columbus Asset Advisors LLC, Goldman Sachs Group Inc., Hawk Ridge Capital Management LP and Stifel Financial Corp. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $2.06.

TherapeuticsMD has a market capitalization of $558.63 million and generates $49.65 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. TherapeuticsMD employs 241 workers across the globe.View Additional Information About TherapeuticsMD.

The official website for TherapeuticsMD is http://www.therapeuticsmd.com/.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]